Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 and type 1 diabetes have opposing effects on the systemic murine complement alternative pathway.

iScience·2026
Same author

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

Nature communications·2026
Same author

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Cancer immunology research·2026
Same author

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Cancer cell·2026
Same author

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity.

Cancer cell·2026
Same author

Insights and perspectives into the discovery of complement-related biomarkers in cancer.

Current opinion in immunology·2025

Related Experiment Video

Updated: May 30, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.8K

A mouse model to assess immunotherapy-related colitis.

Yaiza Senent1, Ana Remírez2, Beatriz Tavira3

  • 1Laboratory of Translational Oncology, Program in Solid Tumors, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, Universidad de Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain.

Methods in Cell Biology
|January 25, 2025
PubMed
Summary

Combined PD-1 and CTLA-4 blockade shows efficacy but causes severe immune-related adverse events (irAEs), particularly colitis. This study presents a novel mouse model to better study immunotherapy-induced colitis, aiding future research and treatment strategies.

Keywords:
Cancer immunotherapyColitisImmune-related adverse eventsMouse colitis model

More Related Videos

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

12.9K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K

Related Experiment Videos

Last Updated: May 30, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.8K
Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

12.9K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K

Area of Science:

  • Immunology
  • Oncology
  • Gastroenterology

Background:

  • Combined blockade of PD-1 and CTLA-4 immune checkpoints demonstrates significant efficacy across various cancers.
  • Immune-related adverse events (irAEs), especially colitis, are a significant challenge, often necessitating treatment cessation and limiting therapeutic potential.

Purpose of the Study:

  • To develop and validate a mouse model that accurately recapitulates the key features of immunotherapy-related colitis.
  • To provide a preclinical tool for investigating the mechanisms underlying colitis induced by combined immune checkpoint blockade.

Main Methods:

  • Utilized a mouse model subjected to combined CTLA-4 and PD-1 blockade.
  • Induced colitis using dextran sulfate sodium (DSS).
  • Assessed the exacerbation of DSS-induced colitis by combined immune checkpoint blockade.

Main Results:

  • Combined CTLA-4 and PD-1 blockade significantly worsened the effects of DSS-induced colitis in the mouse model.
  • The model demonstrated key pathophysiological features relevant to human immunotherapy-related colitis.

Conclusions:

  • The developed mouse model serves as a valuable preclinical tool for studying immunotherapy-related colitis.
  • This model can facilitate research into the mechanisms and potential therapeutic interventions for colitis associated with immune checkpoint inhibitors.